These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18452075)

  • 1. Hyper-CVAD in mantle-cell lymphoma: really "hyper" or just hype?
    Dreyling M
    Leuk Lymphoma; 2008 Jun; 49(6):1017-8. PubMed ID: 18452075
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
    Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
    Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD.
    Shah JJ; Fayad L; Romaguera J
    Blood; 2008 Sep; 112(6):2583; author reply 2583-4. PubMed ID: 18779406
    [No Abstract]   [Full Text] [Related]  

  • 4. PET-CT confirmed complete remission and MRD negativity in mantle cell lymphoma patients treated with R-hyper-CVAD results in excellent outcome in the absence of autologous stem cell transplantation: a single-centre case for a transplant-free approach.
    Htet S; Lane S; Kipp D; Rose H; Campbell P
    Intern Med J; 2016 Sep; 46(9):1113-4. PubMed ID: 27633474
    [No Abstract]   [Full Text] [Related]  

  • 5. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
    Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
    Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
    Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.
    Kamdar M; Li H; Chen RW; Rimsza LM; Leblanc ML; Fenske TS; Shea TC; Barr PM; Phillips TJ; Leonard JP; Kahl BS; Friedberg JW; Smith SM
    Blood Adv; 2019 Oct; 3(20):3132-3135. PubMed ID: 31648328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
    Chang JE; Li H; Smith MR; Gascoyne RD; Paietta EM; Yang DT; Advani RH; Horning SJ; Kahl BS
    Blood; 2014 Mar; 123(11):1665-73. PubMed ID: 24458437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.
    Galimberti S; Palumbo GA; Caracciolo F; Benedetti E; Pelosini M; Brizzi S; Ciabatti E; Fazzi R; Stelitano C; Quintana G; Conte E; Tibullo D; Di Raimondo F; Petrini M
    J Chemother; 2007 Jun; 19(3):315-21. PubMed ID: 17594928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular indicators of prognosis in mantle cell lymphoma in the era of R-hyper-CVAD: still an open issue.
    Morabito F; Gentile M
    Leuk Lymphoma; 2007 Aug; 48(8):1461-2. PubMed ID: 17701572
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficacy of modified Hyper-CVAD regimen on non-Hodgkin's lymphoma and safety evaluation].
    Shi W; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Dong M; Liu P; Qin Y; Yang S; Gui L; Lv Z
    Ai Zheng; 2009 Oct; 28(10):1083-7. PubMed ID: 19799818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphoblastic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Büyükçelik A; Yalçin B; Utkan G; Doruk H
    Cancer; 2004 Sep; 101(5):1100-1; author reply 1101. PubMed ID: 15329922
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
    Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
    Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen.
    Shapiro M; Wasik MA; Junkins-Hopkins JM; Rook AH; Vittorio CC; Itakura H; Frankel MC; Georgala S; Schuster SJ
    Am J Hematol; 2003 Sep; 74(1):46-51. PubMed ID: 12949889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review.
    Alwasaidi TA; Hamadah A; Altouri S; Tay J; McDiarmid S; Faught C; Allan D; Huebsch L; Bredeson C; Bence-Bruckler I
    Cancer Med; 2015 Dec; 4(12):1817-27. PubMed ID: 26432256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
    El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.
    Jeong SH; Moon JH; Kim JS; Yang DH; Park Y; Cho SG; Kwak JY; Eom HS; Won JH; Hong JS; Oh SY; Lee HS; Kim SJ
    Ann Hematol; 2015 Apr; 94(4):617-25. PubMed ID: 25465233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Duodenal polyposis disclosing mantle-cell lymphoma].
    Moulin O; Boucher E; Samson T; Coutant G; Helie C; Algayres JP
    Gastroenterol Clin Biol; 2002 Nov; 26(11):1055. PubMed ID: 12483144
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.